Drug intelligence / Profile preview

BR1010

Development stage: Preclinical
Lead developer: BioRay Pharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

BR1010 is an investigational antibody-drug conjugate (ADC) being developed by BioRay Pharmaceutical (Bioray Laboratories) for the treatment of immune-mediated diseases. While some company summaries have associated the candidate with the interleukin-4 receptor (IL-4R), BioRay's official pipeline currently lists the target as undisclosed, distinguishing it from other specific ADC programs like BR2060. The drug is part of BioRay's strategic expansion of ADC technology into the field of immunology, aiming to provide targeted therapy for autoimmune and inflammatory conditions. It is currently in the early stages of development, following BioRay's focus on discovering and developing medicines for immune-mediated diseases and cancer.

Beyond the preview

Go deeper on BR1010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1010.

Explore the full profile